Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) --...
Brain
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq:...
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and...
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card...
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period...
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision...
Kanazawa University research: Scientists develop a new method to measure cellular energy in real time
KANAZAWA, Japan, Nov. 20, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have developed a...
Hyperfine, Inc. to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared...
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),...
Voio Emerges From Stealth to Build Frontier AI for Healthcare
Voio team’s initial open-source release, Pillar-0, is the world’s most accurate AI model for radiology and builds on the success...
Voio Emerges From Stealth to Build Frontier AI for Healthcare
Voio team’s initial open-source release, Pillar-0, is the world’s most accurate AI model for radiology and builds on the success...
Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing Promising Treatments
Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat...
CABHI launches novel Brain Bases to drive the global brain economy
TORONTO, Nov. 20, 2025 /CNW/ - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, has launched...
Fluents.ai voice AI Introduces “Continuous Context” Omnichannel Platform to End the Era of Disjointed Customer Service
SAN FRANCISCO, Nov. 20, 2025 /PRNewswire/ -- Fluents.ai today announced the launch of Fluents Omnichannel, a unified AI architecture designed...
Bracco Imaging Achieves New Global Milestone with ANVISA Clearance of AiMIFY™ in Brazil
Regulatory Approval Expands Access to AI-Powered Diagnostics Across Latin America, Following FDA and CE Mark Clearances MILAN, Nov. 20, 2025 /PRNewswire/...
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a...
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a...
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Veteran CFO appointment underscores the Company’s commitment to building a strong leadership team as it advances its clinical and commercial...
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...